Trial results

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

NCT04873050 on ClinicalTrials.gov · last registry update 2025-03-13

Recruiting now, toward 102 participants. Its estimated completion date, 1 January 2026, has passed with no update to the record. Primary outcome, as filed: Regression to normoglycemia. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Woman's

Sponsor type

Other

Enrollment

102

Started

2022-01-13

Primary completion

2026-01-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Regression to normoglycemia

Conditions studied

Pre Diabetes · Postpartum Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.